申请人:Gamida Cell Ltd.
公开号:EP2206773A1
公开(公告)日:2010-07-14
The present invention relates to a method of expanding a population of CD34+ hematopoietic stem cells ex-vivo, while at the same time, inhibiting differentiation of the stem cells ex-vivo, the method comprising: (a) culturing said CD34+ hematopoietic stem cells ex-vivo under conditions allowing for cell proliferation, said conditions which comprise providing nutrients, serum and a combination of cytokines including stem cell factor, thrombopoietin, FLt3 ligand, IL-6 and IL-3, and (b) in the same culture medium providing nicotinamide in an amount between 1.0 mM to 10 mM, wherein said cells are cultured for a culture period resulting in expanding the population of CD34+ hematopoietic stem cells while inhibiting differentiation of said CD34+ hematopoietic stem cells ex-vivo to produce an expanded CD34+ hematopoietic stem cell population with an increased proportion of CD34+/Lin- and CD34+/CD38- cells in the expanded culture as compared to CD34+ cells cultured in the presence of cytokines and nutrients without exogenously added nicotinamide.
本发明涉及一种体内外扩增CD34+造血干细胞群体,同时抑制体内外干细胞分化的方法,该方法包括:(a) 在允许细胞增殖的条件下体内外培养所述 CD34+造血干细胞,所述条件包括提供营养物质、血清和细胞因子组合,包括干细胞因子、血小板生成素、FLt3 配体、IL-6 和 IL-3,以及 (b) 在相同的培养基中提供烟酰胺,其量在 1.0 mM 至 10 mM,其中所述细胞培养一段培养期,导致扩大 CD34+ 造血干细胞群,同时抑制所述 CD34+ 造血干细胞的体外分化,以产生扩大的 CD34+ 造血干细胞群,与在细胞因子和营养物质存在下培养的不外源添加烟酰胺的 CD34+ 细胞相比,扩大的培养物中 CD34+/Lin- 和 CD34+/CD38- 细胞比例增加。